Middlefield Income Plus II Corp T.MIP

Mistral Pharma to Present at BioContact 2007

[I_luv_GVG]

Hello everyone, Mistral Pharma to Present at BioContact 2007 10/1/2007 MONTREAL, QUEBEC, Oct 01, 2007 (MARKET WIRE via COMTEX News Network) -- Mistral Pharma Inc. (TSX VENTURE: MIP) announced today that it will be a presenter at the BIOCONTACT 2007 conference at the Chateau Frontenac in Quebec city. This presentation will be given by Ms. Dalal Manoli, Vice President, Sales & Marketing of Mistral Pharma, on October 4, 2007 in the Place d'Armes room at 2 p.m. "BIOCONTACT 2007 is a great opportunity to showcase Mistral Pharma to the investment community and to present our exciting projects and commercial partnership opportunities" commented Ms. Danoli. About BioContact 2007 BioContact is a partnership symposium gathering over 1200 participants. More than 150 biopharmaceutical companies, coming from Canada, the United States, Asia and Europe, will be presenting in different sectors of activities (diagnostics, therapeutics, and services) and disciplines: cancer, cardiology, drug delivery systems, endocrinology / virology, genomics / proteomics, immunology / infectiology, neurobiology, medical technologies, services. For more information visit the BioContact website at www.biocontact.qc.ca. About Mistral Pharma Inc. Mistral Pharma Inc. is an innovative pharmaceutical company that is active in the reformulation and the commercialization of already-marketed drugs. Its branded drug delivery products, MIST-B01 & MIST-B02, showed positive results at their respective first pilot clinical trials. Mistral also has the Canadian rights to Instillagel(R), a local anesthetic and antiseptic combination product used for urology procedures which is expected to be launched in Canada during Q4 2007. Mistral positions itself as a development and marketing partner for pharmaceutical companies. Additional information about Mistral Pharma can be obtained on Mistral Pharma's website at www.mistralpharma.com. Forward-looking Statements Except for historical information provided herein, this press release may contain information and statements of a forward-looking nature concerning the future performance of Mistral Pharma. These statements are based on assumptions and uncertainties as well as on Management's best possible evaluation of future events. Such factors may include, without excluding other considerations, fluctuations in quarterly reults, evolution in customer demand for Mistral Pharma's products, the impact of price pressures exerted by competitors, results from clinical studies and regulatory approval process as well as general market trends or economic changes. As a result, readers are advised that actual results may differ from expected results. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release. Contacts: Mistral Pharma Inc. Bertrand F. Bolduc, B.Pharm., MBA President and Chief Executive Officer 514-421-1717 #2224 [e-mail] Mistral Pharma Inc. Alain Provencher, CA, CF Vice President, Finance and Chief Financial Officer 514-421-1717 #2222 [e-mail] SOURCE: Mistral Pharma Inc. mailto:[e-mail] mailto:[e-mail] GLTA, I_luv_GVG